The meeting focused on discussing recent developments in the kratom industry, including a new Health Advisory from Watchung, New Jersey, and updates on regulatory challenges. Participants shared concerns about misinformation campaigns and the need for better education about kratom's uses and safety. They also discussed the potential impact of new synthetic opioids, particularly 7-OH, and the need for more research and responsible regulation.
The group explored ideas for improving advocacy efforts, including better communication with vendors and customers. They also touched on the importance of proper testing and quality control in the kratom supply chain. The conversation concluded with updates on personal experiences and the dedication of some industry members to maintaining high standards in the face of challenges.
Summary
Kratom Regulation and Advocacy Challenges
The group discussed a new Kratom Health Advisory for Wachong, New Jersey, from the Middlebrook Regional Health Commission, which contains alarmist language about Kratom. Christopher shared his experience with a Massachusetts town that initially opposed Kratom but later reversed their position after receiving more information. The group expressed concerns about pharmaceutical companies potentially gaining exclusive access to Kratom through research and regulation, which could limit public access. They also discussed Washington State's proposed 96% tax on Kratom products and the challenges of getting vendors involved in advocacy efforts.
Kratom and Synthetic Opioids Discussion
The group discussed the mention of synthetic 7OH as a new opioid in a White House press conference, with Christopher sharing a YouTube link to the relevant segment. They debated the implications for Kratom, noting that while the DOJ is addressing synthetic opioids, Kratom itself remains untargeted. Christopher emphasized his company's commitment to customer education and proper dosing, contrasting with what he sees as reckless practices in the industry.